 |
Title 
|
|
|
|
Phase
|
|
|
|
Protocol
IDs
|
|
|
| |
"Touch 2 Screen" Multi-Media Colorectal Cancer Screening Intervention
|
|
|
|
No phase specified
|
|
|
|
1RO1CA119098-01
NCT00594113
|
|
| |
1-methyl-d-tryptophan in Treating Patients With Relapsed or Refractory Solid Tumors
|
|
|
|
Phase I
|
|
|
|
VU-VICC-PHI-0814
VICCPHI0814, NLGC-NLG-2100, IRB#080257, VICTR-1855, NCT00788086
|
|
| |
1stline Study Capecitabine Administered on Continuous Way Plus Oxaliplatin&Bevacizumab Every 2weeks in Metastatic CCR.
|
|
|
|
Phase II
|
|
|
|
XELOXAVBISEMANAL
NCT00345696
|
|
| |
5-Fluorouracil, Bevacizumab, and Radiation Followed by Modified FOLFOX6 and Bevacizumab in Stage I/II Rectal Cancer
|
|
|
|
Phase II
|
|
|
|
SCRI GI 65
AVF3105s, NCT00308516
|
|
| |
5FU/VL Vs LV5FU2 + CPT11 in Stage II-III Resected Rectal Cancer
|
|
|
|
Phase III
|
|
|
|
AERO-R98
NCT00189657
|
|
| |
A Clinical Study of PHY906 as a Modulator of CPT-11 in Patients With Metastatic Colorectal Cancer
|
|
|
|
Phase II, Phase I
|
|
|
|
0706002781
ACS IRG 58-012-49, NCT00730158
|
|
| |
A Dose-Escalation Study of RO5083945 in Patients With Metastatic and/or Locally Advanced Malignant Epidermal Growth Factor Receptor (EGFR)+ Solid Tumors.
|
|
|
|
Phase I
|
|
|
|
BO21495
2007-005939-28, NCT00721266
|
|
| |
A Multi-Center Randomised Controlled Study to Evaluate Laparoscopic Versus Open Surgery for Colorectal Cancer
|
|
|
|
Phase II
|
|
|
|
BJLS01
NCT00788281
|
|
| |
A New Agent DAVANAT in Combination With 5-FU, Avastin and Leucovorin in Subjects With Colorectal Cancer
|
|
|
|
Phase II
|
|
|
|
DAVFU006
NCT00388700
|
|
| |
A Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-Line Therapy After FOLFOX (or XELOX) Plus Bevacizumab in Patients With Mestastatic Colorectal Cancer
|
|
|
|
Phase I
|
|
|
|
CRAD001C2242
NCT00478634
|
|
